Communiqués AstraZeneca PLC Nasdaq Stockholm

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm 18:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
1 591,50 ^SEK	+1,08%		+1,11%	-6,57%

02:55	Les résultats de l’essai sur l’hypophosphatasie (HPP) d’AstraZeneca ne sont pas statistiquement significatifs	AN
09/10	Bourse : ça bouge chez Saint-Laurent (Kering) et BNP Paribas, SpaceX s'attaque aux opérateurs mobiles

Communiqués

11/10	AstraZeneca : Efzimfotase alfa showed numerical improvement in Six-Minute Walk Test achieving mean difference of 17.05 metres vs placebo in treatment-naïve adolescents and adults with hypophosphatasia at week 25 in HICKORY Phase III trial	PU
08/10	SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology	AQ
06/10	AstraZeneca : Alexion to showcase Phase III data in hypophosphatasia and hypoparathyroidism at ASBMR 2026 Annual Meeting	PU
05/10	AstraZeneca opens new global strategic R&D center in Kendall Square, Cambridge, Massachusetts	BU
28/09	AstraZeneca : announces strategic equity investment and clinical collaboration with Summit Therapeutics to advance leading ADC combination strategy in cancer	PU
25/09	Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin granted Priority Review in the US for patients with muscle-invasive bladder cancer	BU
24/09	AstraZeneca : Alexion advances pioneering leadership in gMG care with data at 2026 AANEM Annual Meeting and MGFA Scientific Session	PU
21/09	University of Dundee: Tayside team recruit first global participant in clinical trial for Chronic Kidney Disease	AQ
18/09	AstraZeneca : Klygefa (gefurulimab) recommended for approval in the EU by CHMP for the treatment of adults with generalised myasthenia gravis (gMG)	PU
18/09	Big Picture Bio Founded to Identify, Design and Optimise Promising Cancer Combination Therapies	AQ
18/09	Onco360(R) Has Been Selected as a National Pharmacy Partner for ETCAMAH (camizestrant)	AQ
14/09	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial	BU
14/09	TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial	BU
11/09	AstraZeneca : Update on SERENA-4 Phase III trial of Etcamah in combination with palbociclib in upfront 1st-line advanced ER-positive breast cancer	PU
08/09	IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stage small cell lung cancer	BU
08/09	Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	BU
08/09	AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials	PU
05/09	ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	BU
04/09	AstraZeneca : Etcamah in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer	PU
01/09	AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer	BU
01/09	AstraZeneca : Enhertu plus pertuzumab approved in the EU as first new regimen in more than a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer	PU
01/09	AstraZeneca : completes global license agreement for oral EGFR inhibitor Zegfrovy for lung cancer	PU
27/08	TEZSPIRE demonstrates positive Phase III results in eosinophilic esophagitis across both co-primary and all key secondary endpoints	BU
20/08	Foresite Labs Appoints Dr. Jorge Reis-Filho to Chief Strategy Officer and Operating Partner; Joins Foresite Capital as Venture Partner	AQ
18/08	AstraZeneca - Update on eVOLVE-Lung02 Phase III trial of volrustomig plus chemotherapy in metastatic non-small cell lung cancer	AQ